By Sabela Ojea
Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.
Shares rise 10%, to $2.14, in after-hours trading Tuesday. Through the close, the stock has more than tripled since the beginning of the year.
The genomic-medicine company said it is preparing to initiate enrollment of patients in the phase 1/2 study for the ST-503 program, an investigational epigenetic regulator.
Overall, the company plans to initiate patient enrollment in mid-2025.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
November 19, 2024 16:41 ET (21:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。